ClinicalTrials.gg
RecruitingNCT07197671Updated Aug 19, 2026

Y-NM600 in Patients Receiving Anti-PD-1 or Anti-PD-L1 for Metastatic Cancer

A Phase 1 interventional study of 90Y-NM600 in Metastatic Cancer, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-19.

Sponsored by University of Wisconsin, Madison · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison — 4 open to participants now, 5 under way, none of them phase 3. Neoplasm Metastasis · University of Wisconsin, Madison.

Planned enrollment
3rd of 12
60 · median 18
Started
2026
with 1 other
Phase 1
3 of 14
1 open now
Registered
13th of 14
by date

Among the 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison, this one is the 3rd largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 13th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

4 of the 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Neoplasm Metastasis by University of Wisconsin, Madison, or all of them as a file.
02

Study summary

Participants with metastatic cancer who are taking anti-PD-1 or anti-PD-L1 therapy will be enrolled to assess the safety of and find the optimal dose for radioactive imaging agents and to explore whether these agents will make current drug therapies work better. Up to 60 participants will be enrolled and can expect to be on study for up to 9 months.

Read the detailed description

This is a safety study of 86Y-NM600 and 90Y-NM600 and a dose finding study for 90Y-NM600 in patients with metastatic cancers who are receiving an anti-PD-1 or anti-PD-L1 therapy, have persistent disease that is stable or potentially progressive, and will be continuing anti-PD-1 or anti-PD-L1 therapy for another imaging interval per the treating physician. The imaging agent 86Y-NM600 will be injected, and serial positron-emission tomography (PET)/computed tomography (CT) imaging will be performed to enable dosimetry calculations that will be used to determine eligibility for 90Y-NM600.

Phase 1a of the study (dose finding) will enroll 6-24 participants into a 3x3 dose finding plan where 3 participants start at Level 1 (below) and the number of participants with dose limiting toxicities (DLTs) will inform the next 3 participants:

  • 0/3 Escalate to next higher dose level*
  • 1/3 Accrue additional 3 patients at current dose level
  • 1/3 + 0/3 Escalate to next higher dose level*
  • 1/3 + ≥ 1/3 End phase 1a or de-escalate to dose level -1 if at dose level 1
  • ≥ 2/3 End phase 1a or de-escalate to dose level -1 if at dose level 1

Dosing Plan:

  • Level -1: 20 millicurie (mCi) x 1
  • Level 1: 35 mCi x1
  • Level 2: 70 mCi x1
  • Level 3: 105 mCi x1
  • Level 4: 140 mCi x1

Phase 1b (expansion cohort) may enroll up to an additional 36 participants (18 into a single dose cohort, 18 into a multi-dose cohort) with metastatic cancer.

The primary endpoints are to determine the safety of administering 86Y-NM600 for imaging and 90Y-NM600 for delivering radiation in patients with metastatic cancer who are receiving standard-of-care anti-PD-1 or anti-PD-L1 therapy.

03

Conditions studied

  • Metastatic Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant must be informed of the nature of the study and must be able to sign a written .
  2. Participants with or cytologically confirmed squamous cell carcinoma thought to originate from the head and neck region (HNC).
  3. Participants must have solid , non-hematological.
  4. Participants must be under treatment with one of the following FDA-approved standard-of-care or anti-PD-L1 therapies: Pembrolizumab (Keytruda; anti-PD-1 antibody), Nivolumab (Opdivo; anti-PD-1 antibody), Atezolizumab (Tecentriq, anti-PD-L1 antibody), Avelumab (Bavencio; anti-PD-L1 antibody), Durvalumab (Imfinzi; anti-PD-L1 antibody), Cemiplimab (Libtayo; anti-PD-1 antibody), Dostarlimab (Jemperli; anti-PD-1 antibody). Participants may be on additional FDA-approved immunotherapy treatments including anti-CTLA4 therapies or anti-LAG-3 therapies in addition to the anti-PD-1 or anti-PD-L1 backbone therapy. The specific additional therapies allowed are: Ipilimumab (Yervoy; anti-CTLA4 antibody), Tremelimumab (Imjudo; anti-CTLA4 antibody), or Relatlimab (Opdualag; anti-LAG-3).
  5. Participants must have stable disease or concern for progression of their disease on most recent imaging scans yet be continuing on anti-PD1 or anti-PD-L1 therapy, per the treating physician. Participants may continue on anti-CTLA-4 or anti-LAG-3 ICIs if they have already been taking these when assessed to have stable or potentially progressive disease on most recent imaging. Subjects may also discontinue anti-CTLA-4 or anti-LAG-3 ICIs and remain eligible as long as they meet above criteria and continue the anti-PD-1 or anti-PD-L1 component of therapy that they have already been taking.
  6. Participants must have at least one evaluable (measurable) tumor that is radiographically detectable.
  7. Participants must have an (ECOG) performance status of 0 - 2.
  8. Participants must have a of at least 6 months.
  9. People who could become pregnant have a confirmed negative urine pregnancy test within 7 days prior to receiving Y-NM600.
  10. Participants who are not surgically or medically sterile must agree to use an acceptable method of , such as an oral, implantable, injectable, or transdermal hormonal contraceptive, an intrauterine device (IUD), a double barrier method (condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream), or total abstinence during the study participation and for 6 months after last dose of study drug. Participants who could impregnate their sexual partners must also abstain from intercourse for three weeks after Y-NM600 treatment and agree to use condoms at least 2 months after the last dose of this drug. Participants who are for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be people who could become pregnant.
  11. The participant has adequate renal function as defined by calculated creatinine clearance >40 ml/min
  12. The subject has adequate hepatic function as defined by:

    1. total ≤ 1.5 times the (ULN)
    2. (AST) and alanine transaminase (ALT) less than or equal to 3.0 times the ULN
  13. The participant has adequate hematologic function without Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) injection or transfusion in the prior 7 days, as evidenced by:

    1. an (ANC) greater than or equal to 2000 / μL
    2. greater than or equal to 8 g/dL
    3. greater than or equal to 100,000 / μL
  14. For phase 1a, participant must be willing to undergo 2 core needle that are accessible via ultrasound and/or clinical biopsy.
  15. Adequate uptake of 86Y-NM600 (2x red bone marrow) on PET CT imaging.
  16. No grade 2 toxicities that are new compared to baseline and lack a possible alternative explanation (e.g., underlying disease or another known cause) were noted by Day 7 after the 86Y-NM600 infusion. Toxicities with at least a possibly related attribution to disease and/or another cause-even if also considered at least possibly related to 86Y-NM600-are permitted.
  17. No Grade ≥ 3 toxicities that are new compared to baseline were noted by day 7 after 86Y-NM600 infusion.

Exclusion criteria

Exclusion Criteria:

  1. Other concurrent severe and/or uncontrolled concomitant medical or psychiatric conditions (e.g., active or uncontrolled infection, uncontrolled diabetes) that could cause unacceptable safety risks or compromise compliance with the protocol, per investigator discretion.
  2. The participant is taking strong inducers or inhibitors of CYP450 enzymes or drug transporters that cannot be held from at least 30 days prior to administration of 86Y-NM600 through the final 90Y-NM600 infusion without any expected adverse events. Examples include: clarithromycin, erythromycin, diltiazem, itraconazole, ketoconazole, ritonavir, verapamil, phenobarbital, phenytoin, rifampicin, and .
  3. Chemotherapy, radiotherapy, or major surgery within 3 weeks prior to study enrollment (this will be greater than 5 weeks prior to 90Y-NM600 therapy).

    a. For patients receiving prior radiation therapy, the dose to tumor, kidneys, liver, and bone marrow must be recorded, if available.

  4. The participant is pregnant, breastfeeding, or expecting to conceive or could impregnate someone within the projected duration of the trial, starting with the screening visit through 6 months after the last dose of trial treatment.
  5. Any ongoing or active infection, including active tuberculosis, or C, or known infection with the (HIV) that is not well controlled (undetectable viral load by PCR) by anti-retroviral therapy.
  6. Concurrent treatment with any other systemic anti-cancer or agents other than an , anti-PD-L1, anti-CTLA-4, or anti-LAG-3 antibody. Subjects cannot be receiving concomitant chemotherapy, experimental therapy or any other therapy not otherwise outlined by the trial for the purposes of anti-cancer treatment.

    b. Palliative external beam radiation therapy may be delivered to patients during this study if deemed necessary and safe by the treating physician.

    c. Participants can be receiving dual immune checkpoint inhibition with an anti-CTLA-4 antibody or an anti-LAG-3 antibody in addition to an anti-PD-1 or anti-PD-L1 therapy.

  7. Patients with a history of or concurrent second primary within 2 years to study enrollment are excluded, with the exception of patients who have had definitive treatment of a primary skin basal cell, skin squamous cell carcinomas, or localized low or intermediate risk prostate cancer - these subjects are eligible 3 months after completion of definitive treatment for that prior cancer.
  8. Participants that have had total body or hemibody irradiation, or have had prior systemic radioisotope therapy (except for benign thyroid disease)
  9. Any condition requiring the use of , excluding rheumatologic conditions or endocrine conditions treated with stable doses of corticosteroids (equivalent to prednisone 10 mg daily)
  10. Ongoing hemodialysis or peritoneal dialysis
  11. Any known medical condition that predisposes the subject to uncontrolled bleeding such as hemophilia or clotting factor deficiencies
  12. Participants with known genetic conditions causing pre-disposition to RT toxicity (i.e.: Li-Fraumeni, ataxia telangiectasia mutated (ATM) deficiency, active scleroderma, active inflammatory bowel disease, active systemic lupus)
  13. Patients with an implanted defibrillator or with an implanted pacemaker and pacemaker dependency for rate or rhythm control
  14. Patients with repeated demonstration on two EKGs of a interval greater than 470 milliseconds or use of medications known to prolong the QT/QTc interval
  15. Participants who cannot provide independent, legal,
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Phase 1A: Dose Level -1

    20 mCi x 1 90Y-NM600

    Drug: 90Y-NM600

  • Experimental
    Phase 1A: Dose Level 1

    35 mCi x 1 90Y-NM600

    Drug: 90Y-NM600

  • Experimental
    Phase 1A: Dose Level 2

    70 mCi x 1 90Y-NM600

    Drug: 90Y-NM600

  • Experimental
    Phase 1A: Dose Level 3

    105 mCi x 1 90Y-NM600

    Drug: 90Y-NM600

  • Experimental
    Phase 1A: Dose Level 4

    140 mCi x 1 90Y-NM600

    Drug: 90Y-NM600

  • Experimental
    Phase 1B: Single Dose

    Informed by Phase 1A

    Drug: 90Y-NM600

  • Experimental
    Phase 1B: Multi-dose

    Informed by Phase 1A and Single Dose Phase 1B

    Drug: 90Y-NM600

Interventions

  • Drug90Y-NM600

    NM600 is a tumor-selective, pan-cancer, targeted radionuclide therapy (TRT) with theranostic capacity

    Also known as: alkylphosphocholine (APCh) analog

06

What researchers measure

Primary outcomes

  1. Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600

    Toxicities greater than or equal to Grade 3 at least possibly related to 86Y-NM600 by day 7 (greater than 10 half-lives of 86Y) after 86Y-NM600 injection, as defined by the NCI CTCAE version 5.0.

    Time frame: baseline screening, Day 7 after 86Y-NM600 injection

  2. Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600

    Toxicities greater than or equal to Grade 3 at least possibly related to 90Y-NM600 by day 42 after final 90Y-NM600 injection, as defined by the NCI CTCAE version 5.0. Time points of investigation include: * baseline screening * Phase 1A: post injection week 1, week 2, week 3, week 4 * Phase 1B: 7 days after each injection, 30 days and 42 days after final injection

    Time frame: up to 9 months on study

Secondary outcomes

  1. Pharmacokinetics of Y-NM600: Blood concentration verse time curve

    Blood concentration verse time curve, blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, \*2.0 hours, 4.0 hours, 24 hour, and \*48 hours after infusion (\*Phase 1A only)

    Time frame: 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hour, and *48 hours after infusion (*Phase 1A only)

  2. Pharmacokinetics of Y-NM600: Time to reach maximum concentration of Y-NM600 in Blood

    Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, \*2.0 hours, 4.0 hours, 24 hour, and \*48 hours after infusion (\*Phase 1A only)

    Time frame: Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hour, and *48 hours after infusion (*Phase 1A only)

  3. Pharmacokinetics of Y-NM600: Blood Radioactivity from Y-NM600

    Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, \*2.0 hours, 4.0 hours, 24 hour, and \*48 hours after infusion (\*Phase 1A only)

    Time frame: Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hours, and *48 hours after infusion (*Phase 1A only)

  4. Pharmacokinetics of Y-NM600: Physiological Half-life of Y-NM600

    Phase 1a: Blood draws at estimated Cmax 3-5 min after end of infusion (+/- 5 min), 0.5 hours (+/- 15 min), 2.0 hours (+/- 30 min), 4.0 hours (+/- 30 min), 24 hours (+/- 120 min), and 48 hours (+/- 120 min) after infusion. Phase 1b: Blood draws at estimated Cmax 3-5 min after end of infusion (+/- 5 min), 0.5 hours (+/- 15 min), 4.0 hours (+/- 30 min), and 24 hours (+/- 120 min) after infusion. Cumulative urine collection will be done for 6 hours with specific samples collected and pooled at 0.5 hours (+/- 15 min), 3 hours (+/- 30 min), and at 5 hours (+/- 30 min) after infusion.

    Time frame: Blood draws at estimated Cmax 3-5 min after end of infusion, 0.5 hours, *2.0 hours, 4.0 hours, 24 hours, and *48 hours after infusion (*Phase 1A only)

  5. Proportion of Participants with 2-fold or greater uptake of 86Y-NM600 in tumor site compared to red bone marrow

    Assessed via PET/CT 48-72 hours after 86Y-NM600 infusion as Maximum Standardized Uptake Value (SUVmax) at tumor sites previously identified by standard of care imaging and at a site of red bone marrow.

    Time frame: 48-72 hours after 86Y-NM600 infusion

  6. Overall Response Rate (ORR) by iRECIST at 12 weeks after final 90Y-NM600 injection (D1)

    ORR will include iCR and iPR and will be determined as per iRECIST, by investigator assessment.

    Time frame: baseline, standard-of-care imaging 12 weeks after D1

  7. Safe and Effective Dose Level for Phase 1B

    A recommended phase 1b single treatment dose level is based on the following criteria: 1) a dose level resulting in less than 33 percent of participants with Dose Limiting Toxicities by 42 days after final 90Y-NM600 injection, 2) the dose level with the greatest ORR among dose levels that meet criteria 1 and the lower dose level if ORR is equal at two dose levels, and 3) the highest dose level that meets criteria 1 if no participants exhibit ORR in any regimen that meets criterion 1. For the multi-dose expansion cohort, the recommended dose will be the single treatment expansion dose level or the next highest dose level for which OLINDA calculations from PET/CT imaging at 48-72 hours after 86Y-NM600 for all enrolled patients predict cumulative mean doses of less than 23 Gy to the kidney, less than 2 Gy to the red bone marrow, and less than 30 Gy to liver in greater 66 percent of participants following three cycles of 90Y-NM600 at the multi-dose expansion cohort dose level.

    Time frame: Phase 1A: baseline, Once per week for four weeks after 90Y-NM600 injection and at day 42 after 90Y-NM600 injection, Standard-of-care imaging 8 weeks after D1 of 90Y-NM600

Other outcomes

  1. Progression Free Survival (PFS)

    PFS is defined as the time from Day 1 of treatment until the criteria for disease progression is met as defined by iRECIST or death as a result of any cause.

    Time frame: Day 1 of treatment, Standard-of-care imaging follow-up ~3 and 6 months after Day 1, Time of disease progression (monitored up to 5 years)

  2. Overall Survival (OS)

    OS is defined as time from Day 1 of treatment until death as a result of any cause.

    Time frame: Day 1 of treatment, Standard-of-care imaging follow-up ~3 and 6 months after Day 1, Time of disease progression, Death (monitored up to 5 years)

  3. Duration of Response

    Duration of response is the period measured from the time that measurement criteria are met for immune complete response (iCR), immune partial response (iPR), or immune-related stable disease (iSD) (whichever status is recorded first) until the date that recurrent or iPD is objectively documented.

    Time frame: Day 1 of treatment, Standard-of-care imaging follow-up ~3 and 6 months after Day 1, Time of disease progression (monitored up to 5 years)

  4. EORTC QLQ-C30

    Determine the impact of 90Y-NM600 on patient-reported health-related quality of life (HRQoL) by assessing the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 is scored from 0-100 where higher scores indicate a better quality of life.

    Time frame: baseline, 1 week after Day 1, 12 weeks after Day 1

  5. EQ-5D Score

    Determine the impact of 90Y-NM600 on patient-reported health-related quality of life (HRQoL) by assessing the EQ-5D. The EQ-5D is scored between 0-1 where better quality of life is closer to 1.

    Time frame: baseline, 1 week after Day 1, 12 weeks after Day 1

  6. Tumor Heterogeneity

    Mean, minimum, and maximum dose predicted for 86Y-NM600 and 90Y-NM600 in tumors greater than 2 cm and for select normal organs \[kidney, liver, red bone marrow, blood (2 cm region of abdominal aorta that is great than 1 cm away from any identified tumor site)\] will be determined from three serial 86Y-NM600 PET/CT images. When feasible, this will be performed for all tumor sites greater than 2 cm in any diameter. If the reading radiologist determines this is not feasible, then 5 tumors greater than 2cm will be randomly chosen and dosimetry evaluated at these sites.

    Time frame: PET/CT imaging at 1-6 hours, 18-36 hours, and 48-72 hours after 86Y-NM600 infusion

  7. Tumor Expression of Immune Susceptibility Markers

    Expression of PD-L1, MHC-1, VCAM-1, and IFNβ mRNA by polymerase chain reaction (PCR) on CD45- cells isolated from disaggregated tumor biopsies.

    Time frame: Pre-treatment baseline, 1 week after Day 1

  8. 90Y-NM600 Tumor Microenvironment Immunologic Activation

    Sorted CD45+ cells isolated from disaggregated tumor biopsies will be analyzed by scRNAseq

    Time frame: Pre-treatment baseline, 1 week after Day 1

  9. Count of Circulating Tumor Cells (CTCs)

    CTCs captured by CapioCyte will be quantified, radioactivity directly measured, and mRNA extracted for PCR analysis of PD-L1, MHC-1, VCAM-1, and IFNβ expression.

    Time frame: Pre-treatment baseline, 1 week after Day 1

  10. Radioactivity of Circulating Tumor Cells (CTCs)

    CTCs captured by CapioCyte will be quantified, radioactivity directly measured, and mRNA extracted for PCR analysis of PD-L1, MHC-1, VCAM-1, and IFNβ expression.

    Time frame: Pre-treatment baseline, 1 week after Day 1

  11. Expression of Circulating Tumor Cells (CTCs)

    CTCs captured by CapioCyte will be quantified, radioactivity directly measured, and mRNA extracted for PCR analysis of PD-L1, MHC-1, VCAM-1, and IFNβ expression.

    Time frame: Pre-treatment baseline, 1 week after Day 1

  12. Phenotype of CD8+ T cells

    Peripheral blood mononuclear cells (PBMCs) will be sorted to isolate CD8+ T cells and these will be evaluated by IsoPlexis single cell proteomics assay and by deep sequencing of the T cell receptor.

    Time frame: Pre-treatment, Every 4 weeks after Day 1

  13. Mutation Burden of Circulating Tumor DNA

    Measure changes in ctDNA fraction, tumor mutation burden, and the clonal evolution of tumors with treatment.

    Time frame: Pre-treatment baseline, 1 week after Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Sep 2028, 22 months later.

Of 209 non-industry phase 1 interventional studies under Neoplasm Metastasis, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 98. This study's planned 22 months is below that.

Counting every sponsor, half of 498 studies reached it within 54 months; a quarter within 33 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 15, 2025
First posted
Sep 29, 2025
StartEst.
Nov 1, 2026
Primary completionEst.
Sep 2028
CompletionEst.
Sep 2028
Last update
Aug 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07197671
Collaborators
Archeus Technologies, Inc., National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Sep 29, 2025
Start date
Nov 1, 2026 (estimated)
Primary completion
Sep 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Aug 19, 2026

Study contacts

Cancer Connect
Contact
clinicaltrials@cancer.wisc.edu
800-622-8922
Grace Blitzer, MD
principal investigator · UW Carbone Cancer Center
Justine Bruce, MD
principal investigator · UW Carbone Cancer Center
Zachary Morris, PhD
study chair · UW Carbone Cancer Center
Paul Harari, MD
study chair · UW Carbone Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion